10-Q: Cartesian Therapeutics Reports Q2 2025 Net Income

Cartesian Therapeutics reported a net income of $15.9 million for Q2 2025, driven by fair value adjustments, despite a significant drop in collaboration revenue.

Summary

• Reported a net income of $15.9 million for the three months ended June 30, 2025, compared to a net income of $13.8 million for the same period in 2024.
• Incurred a net loss of $1.8 million for the six months ended June 30, 2025, a significant improvement from a net loss of $43.0 million for the six months ended June 30, 2024.
• Collaboration and license revenue decreased to $0 for Q2 2025 from $33.3 million in Q2 2024, primarily due to a $30.0 million development milestone recognized in Q2 2024 and the termination of the Astellas Agreement.
• Research and development expenses increased by 17% to $14.9 million in Q2 2025 from $12.7 million in Q2 2024, driven by the ongoing Phase 3 AURORA trial for Descartes-08 and headcount growth.
• General and administrative expenses increased slightly to $7.2 million in Q2 2025 from $7.0 million in Q2 2024.
• Cash, cash equivalents, and restricted cash totaled $162.1 million as of June 30, 2025, down from $214.3 million as of December 31, 2024.
• The company believes its existing cash resources will fund operations into mid-2027.
• Accumulated deficit stood at $693.9 million as of June 30, 2025.

Sentiment

Score: 6

Explanation: The financial results show a significant improvement in net income/loss due to non-cash fair value adjustments, which is positive on paper but not indicative of operational profitability. The company maintains a reasonable cash runway into mid-2027, supporting ongoing clinical trials. However, the substantial drop in collaboration revenue and continued operational losses highlight the challenges of a clinical-stage biotech. The progress of Descartes-08 in Phase 3 is a key positive, but the long path to commercialization and reliance on future capital raises introduce significant risk.

Positives

• Achieved a net income of $15.9 million in Q2 2025, an increase from $13.8 million in Q2 2024.
• Reduced net loss for the six months ended June 30, 2025, to $1.8 million from $43.0 million in the prior year period, largely due to favorable fair value adjustments.
• Maintained a cash, cash equivalents, and restricted cash balance of $162.1 million as of June 30, 2025, which is projected to fund operations into mid-2027.
• Recognized significant income from the decrease in the fair value of contingent value right (CVR) liability, totaling $35.3 million in Q2 2025 and $35.6 million in H1 2025.
• Recorded income from the decrease in the fair value of warrant liabilities, amounting to $0.7 million in Q2 2025 and $2.5 million in H1 2025.
• Increased grant revenue to $0.3 million in Q2 2025 from $0.2 million in Q2 2024, and to $1.0 million in H1 2025 from $0.2 million in H1 2024.
• Experienced an increase in interest income to $1.7 million in Q2 2025 from $1.2 million in Q2 2024, and to $3.8 million in H1 2025 from $2.4 million in H1 2024.
• Continued to advance Descartes-08 for Myasthenia Gravis with an ongoing Phase 3 AURORA trial, indicating progress in its lead product candidate.

Negatives

• Experienced a substantial decrease in collaboration and license revenue, falling to $0 in Q2 2025 from $33.3 million in Q2 2024, and to $0.4 million in H1 2025 from $39.1 million in H1 2024, primarily due to the prior year's milestone payment and agreement termination.
• Continued to incur operating losses, with an operating loss of $21.8 million in Q2 2025 and $43.7 million in H1 2025.
• Reported an accumulated deficit of $693.9 million as of June 30, 2025, indicating a history of significant losses.
• Research and development expenses increased, reflecting higher costs associated with clinical trials and personnel.
• Net cash used in operating activities increased to $40.6 million in H1 2025 from $30.4 million in H1 2024.
• Net cash used in financing activities was $8.0 million in H1 2025, a significant shift from $43.2 million provided in H1 2024, largely due to CVR distributions.
• The Astellas Agreement was terminated in June 2024, and the Genovis Agreement was terminated in September 2024, reducing potential future collaboration revenue streams.

Risks

• Future success is dependent on the ability to develop product candidates and ultimately attain and sustain profitable operations.
• The company needs to raise additional capital on favorable terms, which may not be available, to fund its substantial working capital requirements.
• There is uncertainty regarding the generation of significant revenue from product sales for the foreseeable future, as the company currently has no approved products.
• Product candidates require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval, prior to commercialization.
• There is no assurance that research and development will be successfully completed, that intellectual property will be adequately protected, or that any approved products will be commercially viable.
• Clinical development timelines, the probability of success, and development costs can differ materially from expectations, potentially requiring significant additional financial resources and time.
• The company is dependent on third parties, including contract research organizations (CROs), for the conduct of its preclinical studies and clinical trials.
• The company's status as a preclinical and development-stage company means it expects to incur losses in the future and may never achieve or maintain profitability.
• Uncertainties exist with respect to the company's ability to access future capital, which could force it to curtail, delay, or discontinue planned research or development programs.
• The company's approach to therapeutic intervention is unproven, carrying inherent development risks.
• Challenges exist in enrolling patients in clinical trials, timely and successfully completing those trials, and receiving necessary regulatory approvals.
• The company's ability to grow its manufacturing capabilities and resources, and to access facilities and sufficient quantities of product candidates, is critical.
• Maintaining existing or future collaborations or licenses and seeking new partnerships is essential for the company's strategy.
• The impact of macroeconomic conditions, including inflation, changes in interest rates, volatile market conditions, current or potential bank failures, and tariffs, could adversely affect the business.
• Global events, including ongoing conflicts and geopolitical tensions, pose risks to operations.
• The contingent value right (CVR) liability is settled solely through cash flow received under the Sobi License and other Gross Proceeds, with no obligation for the company to fund any amount related to this liability.
• Raising additional capital through the sale of equity instruments could dilute the ownership interest of existing stockholders.
• The company is subject to federal, state, and foreign regulatory requirements, including U.S. Food and Drug Administration (FDA) regulation of its product candidates.
• The ability to obtain and retain key executives and qualified personnel is crucial for the company's success.
• Developments relating to competitors and the industry, including government regulation and policy changes, could impact the company's competitive position.

Future Outlook

The company expects to continue incurring significant expenses and operating losses for the foreseeable future as it advances Descartes-08 for Myasthenia Gravis through Phase 3 development, continues preclinical and clinical-stage product candidates, seeks regulatory approvals, maintains intellectual property, hires additional staff, and incurs public company costs. Existing cash, cash equivalents, and restricted cash of $162.1 million as of June 30, 2025, are expected to fund operations into mid-2027, but additional funding may be pursued through equity, debt, or collaborations.

Management Comments

• We are a clinical-stage biotechnology company pioneering cell therapy for the treatment of autoimmune diseases.
• Our cell therapy is distinguished by its capacity to be dosed repeatedly like conventional drugs, administered in an outpatient setting, and given without pre-treatment chemotherapy required with many conventional cell therapies.
• In our Phase 2b clinical trial in patients with myasthenia gravis, or MG, a chronic autoimmune disease that causes disabling muscle weakness and fatigue, we observed that our lead product candidate, Descartes-08, generated a deep and durable clinical benefit, with 83% of participants maintaining improvements in MG severity scales considered clinically meaningful by expert consensus at six months and sustained improvements in MG severity scales considered clinically meaningful by expert consensus at 12 months.
• Durability of response in MG is commonly measured over a period of 26 to 52 weeks, and maintenance of response over that period is considered durable.
• We believe that our existing cash, cash equivalents, and restricted cash as of June 30, 2025 will enable us to fund our operating expenses and capital expenditure requirements into mid-2027.

Industry Context

Cartesian Therapeutics operates in the highly competitive and rapidly evolving biotechnology industry, specifically focusing on cell therapy for autoimmune diseases. Its approach, utilizing RNA-based CAR-T cells that degrade naturally and can be repeatedly dosed without pre-treatment chemotherapy, positions it uniquely against conventional DNA cell therapies. The company's focus on Myasthenia Gravis with Descartes-08 aligns with a growing trend in the industry to develop targeted therapies for autoimmune conditions. The termination of the Astellas and Genovis agreements highlights the inherent risks and fluctuating nature of collaboration revenues common in early-stage biotech, while the ongoing Phase 3 trial for Descartes-08 signifies progression in a high-value therapeutic area.

Comparison to Industry Standards

• The company's Descartes-08 Phase 2b results for Myasthenia Gravis, showing 83% of participants maintaining clinically meaningful improvements at six months and sustained improvements at 12 months, suggest strong efficacy compared to traditional treatments or other emerging therapies that may require more intensive pre-treatment or have less durable responses.
• The ability to administer Descartes-08 in an outpatient setting and without pre-treatment chemotherapy offers a significant advantage in patient convenience and safety profile compared to many existing CAR-T therapies, which often require inpatient administration and lymphodepleting chemotherapy (e.g., Yescarta (axicabtagene ciloleucel) by Kite Pharma/Gilead, Kymriah (tisagenlecleucel) by Novartis, which are approved for oncology but illustrate the typical CAR-T administration burden).
• The company's accumulated deficit of $693.9 million and continued operating losses are typical for a clinical-stage biotechnology company heavily investing in R&D, similar to peers like smaller biotechs in the autoimmune or cell therapy space (e.g., Kyverna Therapeutics, Cabaletta Bio) that are also pre-revenue and reliant on capital raises and collaborations.
• The cash runway into mid-2027, based on current cash of $162.1 million, is a reasonable timeframe for a clinical-stage biotech, providing sufficient time to reach potential clinical milestones or secure further financing, comparable to the typical 18-24 month runway often targeted by similar companies.

Management Changes

Corporate Governance

Legal Proceedings

• None.

Related Party Transactions

• In connection with the 2023 Private Placement, Dr. Timothy A. Springer (Board member) and TAS Partners LLC (an affiliate of Dr. Springer) purchased 99,140.326 shares of Series A Preferred Stock for $40.0 million during the three months ended March 31, 2024.
• Seven One Eight Three Four Irrevocable Trust (a trust associated with Dr. Murat Kalayoglu, a Board member) also participated in the 2023 Private Placement.
• On March 26, 2024, TAS Partners LLC exercised 65,681 Amended 2019 Warrants, paying $2.9 million in cash, and received 65,681 shares of common stock and 1,970,443 CVRs.
• Directors and executive officers of the company and related parties purchased 2,359,500 shares of Series B Preferred Stock in the 2024 Private Placement.

Stakeholder Impact

• Shareholders: Potential for dilution from future equity raises. The CVRs provide a mechanism for legacy shareholders to receive proceeds from past assets, but the value is subject to fair value adjustments and deductions. Net income per share increased in Q2 2025, but net loss per share persisted in H1 2025.
• Employees: Headcount growth in R&D indicates expansion. Stock-based compensation plans are active, providing incentives. Separation agreement with former CTO and continued vesting for a consulting period impacts a key executive.
• Customers/Patients: Progress in the Phase 3 AURORA trial for Descartes-08 in Myasthenia Gravis offers hope for a new treatment option, potentially administered in an outpatient setting without pre-treatment chemotherapy.
• Creditors: The company's liquidity position with $162.1 million in cash and a runway into mid-2027 provides some comfort, but continued operating losses and reliance on future financing indicate ongoing financial risk.
• Suppliers/Partners: Termination of Astellas and Genovis agreements impacts past partners. Ongoing collaborations with Sobi, Biogen, NCI, and 3SBio continue to be important for development and potential future revenue.

Next Steps

• Continue to advance Descartes-08 for Myasthenia Gravis through Phase 3 development (AURORA trial).
• Continue to develop preclinical and clinical-stage product candidates.
• Seek regulatory approvals for product candidates that successfully complete clinical trials.
• Maintain, expand, and protect intellectual property portfolio, including through licensing arrangements.
• Hire additional staff, including clinical, scientific, and management personnel.
• Potentially pursue additional cash resources through public or private equity or debt financings or by establishing collaborations with other companies.
• The NCI Agreement outlines future commitments including submitting a BLA with respect to a licensed product by Q4 2026, and making a first commercial sale of a licensed product by Q4 2028.
• Milos Miljkovic's Rule 10b5-1(c) trading plan for stock options and potential stock sales will continue until March 31, 2026.
• The initial term of the Third Frederick Lease Agreement Amendment for expansion of premises is expected to commence on September 1, 2025.

Key Dates

Recommendation

The company's financial performance for Q2 2025 shows a net income, primarily driven by non-cash fair value adjustments related to contingent value rights and warrants, rather than core operational profitability. While the cash position of $162.1 million provides a runway into mid-2027, indicating sufficient short-term liquidity, the company continues to incur significant operating losses and will require substantial additional financing to fund its long-term development and potential commercialization efforts. The progress of Descartes-08 into Phase 3 for Myasthenia Gravis is a positive clinical development, but the path to regulatory approval and commercialization is long, costly, and uncertain. The significant decrease in collaboration revenue highlights the volatility of this income stream. Given the early stage of product development, the reliance on future capital raises, and the inherent risks of the biotechnology sector, a 'hold' recommendation is appropriate. Investors should monitor clinical trial progress, future financing activities, and the company's ability to manage its burn rate.

Keywords

Biotechnology, Cell Therapy, Autoimmune Diseases, Myasthenia Gravis, Descartes-08, Clinical Stage, SEC Filing, 10-Q, Financial Results, Research and Development, CAR-T cells, RNA-based CAR-T, Biopharma